Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Scientists in Jennifer Doudna’s lab pull back the veil on their gene-editing process
***
Clustered Regularly Interspaced Palindromic Repeat
***
***
CRISPR is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that had previously infected the prokaryote. They are used to detect and destroy DNA from similar bacteriophages during subsequent infections
And, we’ve posted about CRISPR before: https://medicalexecutivepost.com/2021/07/08/on-crispr-gene-editing/
So now, what is the use of CRISPR for antiobiotics?
***
COMMENTS APPRECIATED
Thank You
***
FINANCIAL PLANNING: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283
***
Share this:
Filed under: "Doctors Only", Career Development, Drugs and Pharma, Ethics, Experts Invited, Health Insurance, Information Technology, Quality Initiatives | Tagged: Clustered Regularly Interspaced Palindromic Rep, CRISPR, Hayden Field, Jennifer Doudna |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Crispr Therapeutics
The genetic information in every cell plays a key role in the body’s aging process. Now, scientists have discovered a way to use the CRISPR-Cas9–based gene editing technology to identify genes that could affect cellular senescence.
Gene therapy is a particularly promising way to fight aging, however these treatments are far from proven or mainstream yet. If successful, these treatments could unlock tremendous value for Crispr Therapeutics (NASDAQ:CRSP).
The company has lost roughly three-quarters of its value since early-2021. However, it’s still worth $3.95 billion — which indicates how exciting this technology is. Investors could keep an eye on this gene editing pioneer.
DEM
LikeLiked by 1 person